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bipolar) increased overtime with monthly average of $1432 (SD
2551). In addition, total cost was also signiﬁcantly associated
with general comorbidities like diabetes mellitus (OR = 1.34;
95% CI 1.14–1.56), cancer (OR 1.73; 1.07–2.63), hypertension
(OR 1.63; 1.41–1.88), COPD (OR 1.41; 1.35–1.96), cerebra-
vascular disease (OR 1.94; 1.59–2.35), and ischemic heart
disease (OR 1.89; 1.53–2.34). CONCLUSION: Bipolar related
cost is associated with bipolar I disorder, psychological disor-
ders, and use of antipsychotics therapy. In addition, the total
health care cost is signiﬁcantly associated with general clinical 
comorbidities.
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OBJECTIVE: The objective is to quantify the epidemiological
patterns and medical cost of patients treated for both Attention-
Deﬁcit/Hyperactivity Disorder (ADHD) and epilepsy
(ADHD/epilepsy). METHODS: We analyzed a de-identiﬁed
administrative claims database (approximately 600,000 lives
under the age of 65, 1998 to 2001) for commercially insured
populations to assess the treated prevalence rate as well as the
incremental cost of epilepsy among ADHD patients 18 years old
or younger. These measures were computed for the ADHD
patients treated for epilepsy (n = 64) compared to a control
group of epilepsy patients without ADHD (“non-ADHD”) of the
same age (n = 107) in a random sample. We investigated the
validity of the results using a similar, supplemental database.
RESULTS: The treated prevalence rate of epilepsy is 1.5%
among ADHD patients versus 0.5% among non-ADHD
patients. The odds ratio of epilepsy treatment given an ADHD
diagnosis is 3.2. ADHD/epilepsy patients are treated for mental
disorders 3.6 times more than non-ADHD patients (41.0% vs.
11.4% of patients, respectively, p < 0.0001). The average annual
costs are $4365 for ADHD/epilepsy patients and $3568 for con-
trols; the difference is not statistically signiﬁcant. These costs
were primarily for non-mental health diagnoses. However, the
cost of mental health treatment of ADHD/epilepsy patients was
15 times higher than that for non-ADHD patients (p = 0.01).
Patterns of results were similar in the second database. However,
because this study relied on insurance claims data, the ﬁndings
apply to clinical practice as opposed to tightly diagnosed
research samples. CONCLUSIONS: Epilepsy is more common
among ADHD patients than the general population.
ADHD/epilepsy patients use more health care services and cost
more than epilepsy-only patients.
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OBJECTIVE: Although it is widely accepted that stimulants are
used as the treatment of choice, many decision makers do not
have appropriate information regarding an optimal ﬁrst-line
agent in treating this patient population. We evaluated the 
cost-effectiveness in choosing methylphenidate (RitalinTM) or
amphetamine/ dextroamphetamine (AMP/DEX) mixed salts
(AdderallTM) as a ﬁrst-line agent in the treatment of ADHD.
METHODS: Decision-tree analysis was performed using
weighted utility and weighted cost outcomes after basing deci-
sions on three treatment arms: Initiation with methylphenidate,
initiation with AMP/DEX, or no treatment. Data inputs such as
efﬁcacy rates, side effects, compliance rates, and school admin-
istration rates were extracted from a literature review. A societal
perspective was used to estimate outcomes in terms of incre-
mental cost and incremental utilities over the time horizon of one
year. RESULTS: In the base case analysis, AMP/DEX dominates
both methylphenidate and using no treatment. The ICE ratio for
AMP/DEX versus no treatment is $21,931/ QALY. Total costs
for the AMP/DEX arm were $2999 with a QALY score of 0.889.
The methylphenidate arm reports total costs of $3043 and a
QALY score of 0.839, and those who received no treatment
achieved total costs of $993 and a QALY score of 0.798. Sensi-








included drug cost and the reduced compliance of medication by
methylphenidate users (61%) versus AMP/DEX users (86%) and
the AMP/DEX response rate. CONCLUSIONS: Generic Adder-
allTM is the dominant strategy over generic RitalinTM given that
compliance and side effect rates are consistently higher for
generic AdderallTM. However, it is difﬁcult to make strong gen-
eralizations about cost-effectiveness between therapies given the
overlapping efﬁcacy rates and similar side effect proﬁles of com-
peting treatments as reported in the literature. Clinicians should
ﬁnd it appropriate to initiate stimulants in the short term regard-
less of the speciﬁc agent available.
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OBJECTIVES: Reportedly, suicide rates are highest among those
aged 65 years and older (elderly) in the US. This study examines
admissions resulting from suicide attempts by elderly persons
and estimates the resulting hospital costs. METHODS: Cases of
suicide attempts by elderly persons were identiﬁed using ICD-9
diagnosis and E-codes. Hospital costs were developed based on
2000 discharge data from 619 hospitals in seven states, 
supplemented with national fee schedules. Cost estimates include
accommodation, ancillary and physician services, reported in
2003 US$. Charges were adjusted using a 0.61 cost-to-charge
ratio and the annual medical care component of the U.S. Con-
sumer Price Index. RESULTS: Of 2129 suicide attempts identi-
ﬁed, 56% were female and 3% were admitted from residential,
nursing or correctional facilities. The mean age was 76 years;
75% were admitted via Emergency Room and 41% spent time
in ICU. Drug overdose was the method of self-inﬂicted injury in
71% of cases. Mean length of stay was 5.9 days (median: 3,
range: 1–261). Mean cost per stay was $11,445 (median: $6005,
range: $498–$610,565). Cumulative cost for all cases was $29.7
million. The inpatient case fatality rate was signiﬁcantly (p =
0.000) higher in males (12%) than females (4%). Of those dis-
charged, 51% went home (6% with home care), 26% to sub-
acute facilities, 20% to a mental health or residential care facility,
and 1% returned to prison. Within 12 months following their
index suicide attempt, 8% were readmitted for another attempt
and survived. CONCLUSIONS: While most of the intentionally
self-inﬂicted injuries by elderly persons who are admitted to hos-
pital are not fatal, elderly males admitted for suicide attempts
are three times more likely to succeed. Although suicide attempts
by elderly persons generate substantial hospital costs, the 
estimates presented reﬂect only a portion of the economic 
consequences of this problem, as most require health services
post-discharge.
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OBJECTIVES: Evaluation of schizophrenic patients requires
measurements that extend, beyond mere estimation of psy-
chopathology symptoms, to assessment of quality of life levels.
The relationship between psychopathology and HRQOL
changes has not been extensively studied. The objective of this
study is to assess correlations between psychopathology (Posi-
tive and Negative Symptom Scale, PANSS) and a disease-speciﬁc
questionnaire, the Quality of Life Scale (QLS), in the evaluation
of schizophrenia patients. METHODS: An open-label, 52-week
follow–up study of 170 patients is being conducted in 8 Greek
public psychiatric hospitals. Patients with mild to moderate
schizophrenia (according to DSM-IV criteria) aged 18–65, hos-
pitalized or outpatients, newly diagnosed or in acute exacerba-
tion were enrolled. Psychopathology was assessed by PANSS
general psychopathology, positive and negative symptom scores.
HRQOL was assessed by QLS total and 4 subscale scores (inter-
personal relationships, instrumental role, intrapsychic founda-
tions and common objects and activities). Correlations analysis
was used to identify the relationship between PANSS and QLS
scores at baseline and at stabilization after 6-months treatment.
Six month follow-up data are presented in this analysis.
RESULTS: At baseline, a weak but statistically signiﬁcant (p <
0.001) association was found between the 4 QLS subscale scores
and PANSS general and negative symptom scores. Correlation
coefﬁcients ranged from r = -0.18 (p < 0.05) (QLS instrumental
role vs. PANSS negative) to r = -0.46 (p < 0.001) (QLS intrapsy-
chic foundation vs. PANSS negative). At six months a stronger
and statistically signiﬁcant association was observed. Correlation
coefﬁcients ranged from r = -0.32 (p < 0.001) (QLS total score
vs. PANSS general) to r = -0.56 (p < 0.001) (QLS intrapsychic
foundation vs. PANSS negative). CONCLUSIONS: The study
reveals a statistically signiﬁcant correlation between PANSS and
QLS at baseline scores, which is improved over the 6-months
follow-up period. HRQL measures and psychopathology seem
to change synchronically; the correlation is enhanced as the
control of schizophrenia symptoms is improved.
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OBJECTIVES: Antipsychotics differ in their impact on prolactin,
and sustained elevation in prolactin levels is associated with
sexual dysfunction. Unlike risperidone, olanzapine is known 
as a prolactin-sparing antipsychotic. This study aimed to: a)
compare olanzapine and risperidone on reported sexual dys-
function during the long-term treatment of schizophrenia
patients in usual care, and b) examine the associations between
sexual dysfunction, medication adherence, and indicators of
well-being for all patients. METHOD: Data of the U.S. Schizo-
phrenia Care and Assessment Program (SCAP), a 3-year obser-
vational study of schizophrenia patients, were used to identify
participants who were treated with olanzapine (N = 330) or
risperidone (N = 216) at enrollment and continued on the drug
for a minimum of 1 year. The SCAP-Health Questionnaire was
used to measure patients’ self-reported medication-related sexual
dysfunction at 6-month intervals. Group differences on changes
in sexual dysfunction levels from baseline up to 3 years were
examined using a mixed model with repeated measures
